Back to Archived News
MorphoSys Further Strengthens US Patent Position on Core Technologies
Tuesday, October 05, 2010
Martinsried, Germany & Munchen, Germany -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that the US Patent and Trademark Office (USPTO) has granted a new patent providing extended protection for the company's CysDisplay technology. The new patent (US 7,785,859) covers the host cells used in this enhanced phage display technology. Currently, the company is prosecuting more than 35 different proprietary patent families worldwide, in addition to about the same number of patent families being pursued in cooperation with its partners.
"Today's news marks yet another step in extending our strong intellectual property portfolio in key pharmaceutical markets like the US," commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG. "We are committed to maximizing the patent protection on our core technologies, as these are essential value-drivers for the company."
CysDisplay is an improved version of phage display in which an antibody is linked to the surface of a bacteriophage via a disulphide bond. Recovery of the antibodies following screening of a library is then effected by reductive cleavage of the disulphide bond, ensuring that all specific binders are eluted independent of their binding affinity to the antigen.
MorphoSys is an independent biotechnology company that develops novel antibodies for therapeutic, diagnostic and research applications. The Company's HuCAL technology is one of the most powerful methods available for generating fully human antibodies. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human health-care. Through its alliances with some of the world's leading pharmaceutical companies, MorphoSys has created a pipeline of more than 60 drug candidates. The Company is expanding its drug pipeline by adding new partnered programs, and by building a portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio, the Company is focused on the areas of oncology and inflammation. Its most advanced program MOR103, a first-in-class, fully human antibody against GM- CSF, is currently tested in a Phase Ib/IIa trial in rheumatoid arthritis patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of its technologies in the diagnostics and research markets. MorphoSys is headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol "MOR". For further information, visithttp://www.morphosys.com/
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay® and RapMAT® are registered trademarks of MorphoSys.
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
Back to Archived News